About Ceretype
Neuromedicine
Ceretype grew out of the desire of its physician-scientist cofounders to translate years of academic research in psychiatric neurobiology and imaging methods development into tools that transform therapeutic development and clinical care. CEO Emily Stern, MD, SAB Chair David Silbersweig, MD and CTO Prantik Kundu, PhD have decades of expertise in functional neuroimaging, as well as a deep understanding of how psychiatric and neurological diseases and treatments affect the brain.
Our Mission
Ceretype provides actionable individual and population insights through unparalleled, commercializable visibility into brain circuitry—offering precision to stakeholders across the global healthcare ecosystem. This solution, led by Ceretype’s visionary team of scientific leaders and expert business professionals will bring new therapeutics to the market faster and revolutionize the treatment of psychiatric and neurological disorders.
